Human choriogonadotropin prior to controlled ovarian stimulation and in vitro fertilization improves implantation, and pregnancy rates
- 107 Downloads
Our purpose was to retrospectively compare controlled ovarian stimulation(COH) in IVF cycles with administration of hCG on the day of menses (D1-hCG) with women not receiving hCG at day 1 of menses (Control).
Data on maternal age, endocrine profile, amount of rFSH required, embryo characteristics, implantation and pregnancy rates were recorded for comparison between D1-hCG (n = 36) and Control (n = 64).
Dose of rFSH required to accomplish COH was significantly lower in D1-hCG. Following ICSI, more top-quality embryos were available for transfer per patient in the D1-hCG and biochemical pregnancy rates per transfer were significantly higher in the D1-hCG. Significantly higher implantation and on-going pregnancy rates per embryo transfer were observed in D1-hCG (64%) compared to Control (41%).
Administration of D1-hCG prior to COH reduces rFSH use and enhances oocyte developmental competence to obtain top quality embryos, and improves implantation and on-going pregnancy rates. At present it is not clear if the benefit is related to producing an embryo that more likely to implant or a more receptive uterus, or merely fortuitous and related to the relatively small power of the study.
KeywordsHuman choriogonadotropin Controlled ovarian hyperstimulation In vitro fertilization Oocyte developmental competence
The authors would like to express appreciation to Claudia Vieira, Beto Jalegretti, Joyce Fioravanti, and Lia Rossi for technical and editorial input and comments. Additionally, the authors thank Dr. Carrie Cosola-Smith and Jeni Chapman for editorial comments.
- 1.Gourgeon A. Regulation of ovarian follicular development in primates: facts and hypotheses. Endocr Rev. 1996;17:121–55.Google Scholar
- 9.Balasch J, Miro F, Burzaco I, Casamitjana R, Civico S, Ballesca JL, et al. The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone. Hum Reprod. 1995;10:1678–83.PubMedGoogle Scholar
- 10.Filicori M, Fazleabas AT, Huhtaniemi I, Licht P, Rao C, Tesarik J, et al. Novel concepts of human chorionic gonadotropin: reproductive system interactions and potential in the management of infertility. Fertil Steril. 2005;84:275–84. doi: 10.1016/j.fertnstert.2005.02.033.PubMedCrossRefGoogle Scholar
- 15.Schipper I, Hop WC, Fauser BC. The follicle-stimulating hormone (FSH) threshold/window concept examined by different interventions with exogenous FSH during the follicular phase of the normal menstrual cycle: duration, rather than magnitude, of FSH increase affects folli. J Clin Endocrinol Metab. 1998;83:1292–8. doi: 10.1210/jc.83.4.1292.PubMedCrossRefGoogle Scholar
- 17.De Placido G, Alviggi C, Perino A, Strina I, Lisi F, Fasolino A, et al. On behalf of the Italian collaborative group on: recombinant human luteinizing hormone recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum Reprod. 2005;20:390–6. doi: 10.1093/humrep/deh625.PubMedCrossRefGoogle Scholar
- 19.Tarlatzis B, Tavmergen E, Szamatowicz M, Barash A, Amit A, Levitas E, et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study. Hum Reprod. 2006;21:90–4. doi: 10.1093/humrep/dei293.PubMedCrossRefGoogle Scholar
- 20.Kolibianakis EM, Kalogeropoulou L, Griesinger G, Papanikolaou EG, Papadimas J, Bontis J, et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum Reprod Update. 2007;13:445–52. doi: 10.1093/humupd/dmm008.PubMedCrossRefGoogle Scholar
- 21.Serafini P, Yadid I, Motta EL, Alegretti JR, Fioravanti J, Coslovsky M. Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial. Fertil Steril. 2006;86:830–8. doi: 10.1016/j.fertnstert.2006.02.110.PubMedCrossRefGoogle Scholar
- 24.Hugues JN, Soussis J, Calderon I, Balasch J, Anderson RA, Romeu A. Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study. Hum Reprod. 2005;20:629–35. doi: 10.1093/humrep/deh682.PubMedCrossRefGoogle Scholar
- 26.Yadid I, Coslowsky M, Ribeiro CV, Motta ELA, Serafini PC. Follicle recruitment for IVF following administration of choriogonadotropin alpha (rec-hCG) on the day of spontaneous menstruation. Hum Reprod. 2005;20(Suppl. 1):i122–8.Google Scholar
- 28.Zelinski-Wooten MB, Hutchison JS, Trinchard-Lugan I, Hess DL, Wolf DP, Stouffer RL. Initiation of periovulatory events in gonadotrophin-stimulated macaques with varying doses of recombinant human chorionic gonadotrophin. Hum Reprod. 1997;12:1877–85. doi: 10.1093/humrep/12.9.1877.PubMedCrossRefGoogle Scholar
- 30.Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PMM, van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod. 2008;23:310–5. doi: 10.1093/humrep/dem305.PubMedCrossRefGoogle Scholar
- 37.Mason HD, Cwyfan-Hughes SC, Heinrich G, Franks S, Holly JMP. Insulin-Like Growth Factor (IGF) I and II, IGF-Binding Proteins, and IGF-Binding Protein Proteases Are Produced by Theta and Stroma of Normal and Polycystic Human Ovaries. Clin Endocrinol Metab. 1996;81:276–84. doi: 10.1210/jc.81.1.276.CrossRefGoogle Scholar